RxDoctor Payments Data

Jonathan Zirna, PA

Medical · Buffalo, NYNPI 1417485871

Payments from drug & device makers

$3,767in general payments, 2019–2025

Across 211 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$702
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$561
  • Pfizer$350
  • Novartis$276
  • Amgen$248
  • Impulse Dynamics (USA) Inc.$236
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,754100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,767 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$26,188
Medicare patients
166
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$132,116
JardianceEmpagliflozin79$92,670
EntrestoSacubitril/Valsartan60$73,252
BrilintaTicagrelor40$33,125
Repatha SureclickEvolocumab39$29,190
XareltoRivaroxaban18$20,392
VascepaIcosapent Ethyl11$4,356
Metoprolol Succinate160$3,198
Atorvastatin Calcium78$1,165
Prasugrel Hcl18$1,024
Valsartan20$953
Rosuvastatin Calcium49$891
Ranolazine ErRanolazine11$851
Ezetimibe36$824
Lisinopril56$547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$350$132,116121 claims
Boehringer IngelheimJardiance$702$92,67079 claims
NovartisEntresto$276$73,25260 claims
AstraZenecaBrilinta$95$33,12540 claims
Johnson & JohnsonXarelto$128$20,39218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.

Other medical in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →